UA126993C2 - Композиція для ерадикації helicobacter pylori - Google Patents

Композиція для ерадикації helicobacter pylori Download PDF

Info

Publication number
UA126993C2
UA126993C2 UAA202101578A UAA202101578A UA126993C2 UA 126993 C2 UA126993 C2 UA 126993C2 UA A202101578 A UAA202101578 A UA A202101578A UA A202101578 A UAA202101578 A UA A202101578A UA 126993 C2 UA126993 C2 UA 126993C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutically acceptable
acceptable salts
clarithromycin
ruiogi
formula
Prior art date
Application number
UAA202101578A
Other languages
English (en)
Ukrainian (uk)
Inventor
Пон Те Кім
Пон Тэ Ким
Тонкю Кім
Тонкю Ким
Ин Чі Кім
Ын Чи Ким
Чі Вон Лі
Чи Вон Ли
Кйонмін Ох
Кйонмин Ох
Ахрон Кім
Ахрон Ким
Кин Соґ Сон
Кын Сог Сон
Схін-Йоун Рю
Схин-Йоун Рю
Ин Кюн Кім
Ын Кюн Ким
Нарее Схін
Нарее Схин
Гюн Чі Кан
Хюн Чи Кан
Че Мін Кім
Чэ Мин Ким
Ю-Кйон Парк
Ганиль Чон
Ханыль Чон
Original Assignee
Гк Інно.Н Корпорейшн
Хк Инно.Н Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гк Інно.Н Корпорейшн, Хк Инно.Н Корпорейшн filed Critical Гк Інно.Н Корпорейшн
Publication of UA126993C2 publication Critical patent/UA126993C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
UAA202101578A 2018-08-29 2019-08-28 Композиція для ерадикації helicobacter pylori UA126993C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180102250 2018-08-29
PCT/KR2019/011017 WO2020045992A1 (en) 2018-08-29 2019-08-28 Composition for eradicating helicobacter pylori

Publications (1)

Publication Number Publication Date
UA126993C2 true UA126993C2 (uk) 2023-03-01

Family

ID=69643254

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA202101578A UA126993C2 (uk) 2018-08-29 2019-08-28 Композиція для ерадикації helicobacter pylori

Country Status (25)

Country Link
US (2) US20210196685A1 (https=)
EP (1) EP3843723B1 (https=)
JP (1) JP7189327B2 (https=)
KR (1) KR20200026118A (https=)
CN (1) CN112638378A (https=)
AR (1) AR116026A1 (https=)
AU (1) AU2019328903B2 (https=)
CA (1) CA3107624C (https=)
DK (1) DK3843723T3 (https=)
EA (1) EA202190622A1 (https=)
ES (1) ES3060114T3 (https=)
FI (1) FI3843723T3 (https=)
GE (2) GEP20227431B (https=)
JO (1) JOP20190201B1 (https=)
LT (1) LT3843723T (https=)
MX (1) MX2021002278A (https=)
MY (1) MY195494A (https=)
PH (1) PH12021550385A1 (https=)
PT (1) PT3843723T (https=)
RS (1) RS67791B1 (https=)
SG (1) SG11202101920WA (https=)
SI (1) SI3843723T1 (https=)
UA (1) UA126993C2 (https=)
UY (1) UY38348A (https=)
WO (1) WO2020045992A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3132575A1 (en) * 2019-04-18 2020-10-22 Thomas Julius Borody Compositions and methods for treating, ameliorating and preventing h. pylori infections
WO2024210689A1 (ko) * 2023-04-07 2024-10-10 제이더블유중외제약 주식회사 벤즈이미다졸 유도체의 염
TW202535382A (zh) * 2023-11-29 2025-09-16 南韓商第一藥品股份有限公司 包含ｚａｓｔａｐｒａｚａｎ或其醫藥上可接受的鹽之用於幽門螺旋桿菌根除的組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753324B2 (en) * 1998-07-15 2004-06-22 Hassan Jomaa Phosphorous organic compounds and their use
KR101088247B1 (ko) * 2005-12-19 2011-11-30 라퀄리아 파마 인코포레이티드 크로메인 치환된 벤즈이미다졸 및 이들의 산 펌프억제제로서의 용도
CN101015694A (zh) * 2006-02-07 2007-08-15 沈阳东宇药业有限公司 一种治疗幽门螺旋杆菌感染的复方口服制剂
HUE056322T2 (hu) * 2015-06-08 2022-02-28 Hk Inno N Corp Benzimidazol-származék alkalmazásai éjszakai savvisszaáramláshoz
WO2017125912A1 (en) * 2016-01-21 2017-07-27 Dexcel Pharma Technologies Ltd. Methods for treating helicobacter infection
KR101829706B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
CN108379258B (zh) * 2017-11-30 2020-02-18 中国医学科学院医药生物技术研究所 瑞香素在抗幽门螺杆菌中的应用

Also Published As

Publication number Publication date
EP3843723A1 (en) 2021-07-07
UY38348A (es) 2020-03-31
KR20200026118A (ko) 2020-03-10
SG11202101920WA (en) 2021-04-29
MX2021002278A (es) 2021-08-11
WO2020045992A1 (en) 2020-03-05
CA3107624C (en) 2023-10-03
BR112021003578A2 (pt) 2021-05-18
AU2019328903A1 (en) 2021-04-29
CN112638378A (zh) 2021-04-09
ES3060114T3 (https=) 2026-03-25
DK3843723T3 (da) 2026-02-09
GEP20227431B (en) 2022-10-25
LT3843723T (lt) 2026-03-25
EP3843723A4 (en) 2022-06-29
AU2019328903A8 (en) 2021-05-27
PH12021550385A1 (en) 2021-09-20
CA3107624A1 (en) 2020-03-05
MY195494A (en) 2023-01-26
JOP20190201A1 (ar) 2020-02-29
US20250241897A1 (en) 2025-07-31
JP2021535910A (ja) 2021-12-23
AR116026A1 (es) 2021-03-25
US20210196685A1 (en) 2021-07-01
PT3843723T (pt) 2026-01-27
EP3843723B1 (en) 2026-01-07
FI3843723T3 (fi) 2026-02-12
JP7189327B2 (ja) 2022-12-13
JOP20190201B1 (ar) 2024-04-18
GEAP202215593A (en) 2022-07-11
EA202190622A1 (ru) 2021-06-10
SI3843723T1 (sl) 2026-04-30
AU2019328903B2 (en) 2023-01-05
RS67791B1 (sr) 2026-03-31

Similar Documents

Publication Publication Date Title
UA126993C2 (uk) Композиція для ерадикації helicobacter pylori
DK2337575T3 (en) A method of treatment with single doses of oritavancin
JP2010522240A (ja) 炎症を処置するための組成物および方法
US20200069652A1 (en) Uses of benzimidazole derivative for nocturnal acid breakthrough
ES2660494T3 (es) Uso de levocetirizina y montelukast en el tratamiento de una lesión traumática
US20070093457A1 (en) Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid
CN114126643A (zh) 包含溶菌酶的广谱抗菌药物制剂及其使用方法
TW202206081A (zh) ９—胺甲基米諾四環素化合物及其用途
WO2016120787A1 (en) Oral n-acetylcysteine in the treatment of upper respiratory tract infections and symptoms
KR20240109355A (ko) 포비돈-요오드를 유효성분으로 함유하는 상기도 염증성 질환의 예방, 개선 또는 치료용 조성물
McLean et al. Relative effectiveness and costs of antiulcer medications as a basis for rational prescribing
US10046052B2 (en) Method and formulation for cold treatment in adults and children with increased safety
EA043853B1 (ru) Композиция для эрадикации helicobacter pylori
Roller et al. Peptic ulcer disease.
Lamsaouri The role of the pharmacist in the pvevention of peptic ulcer disease and its complications
BR112021003578B1 (pt) Composição e método para erradicar helicobacter pylori
JP3937448B2 (ja) Ｈ．ｐｙｌｏｒｉに起因する胃腸障害の処置のためのスピラマイシンの使用
Roller et al. Disease state management: Peptic ulcer disease
Khanna et al. A Systematic Review on Vonoprazan Fumarate Used in the Treatment of GERD
US9402885B2 (en) Method of treating GERD with alpha and beta galactosidases
US20200405783A1 (en) Probiotic for the treatment of psoriasis
Roller et al. Disease state management: Peptic ulcer disease and gastro-oesophageal reflux